A complete narrative review on polypharmacy: role of clinical pharmacist in managing interventions in polypharmacy and improving patient outcomes
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262882Keywords:
Polypharmacy, Clinical pharmacist, Interventions, Medical management, Adverse drug reactionsAbstract
Polypharmacy, commonly defined as the concurrent use of multiple medications, has emerged as a significant global health concern, especially among elderly patients with multimorbidity. It is associated with an increased risk of adverse drug reactions, drug–drug interactions, prolonged hospital stays, and poor medication adherence, ultimately leading to unfavorable clinical outcomes. This review critically evaluates existing literature on polypharmacy, focusing on its etiology, associated risks, and clinical consequences. It examines patient-, physician-, and healthcare system-related factors contributing to inappropriate prescribing. Additionally, the role of clinical pharmacists and the application of assessment tools such as Beers criteria, STOPP/START criteria, and the medication appropriateness index are analyzed. The findings highlight that inappropriate polypharmacy is driven by multiple factors, including fragmented healthcare delivery, lack of medication review, and limited awareness among healthcare providers. Clinical pharmacists play a pivotal role in mitigating these risks by identifying potentially inappropriate medications, conducting medication reviews, and implementing deprescribing strategies. The use of standardized tools and multidisciplinary collaboration has been shown to improve medication appropriateness and patient safety. Polypharmacy remains a complex challenge requiring a coordinated and systematic approach. Integration of clinical pharmacy services into routine healthcare practice significantly enhances medication safety and clinical outcomes. Clinical pharmacists are essential in promoting rational pharmacotherapy and reducing medication-related harm through targeted interventions and patient-centred care.
References
Havelikar U, Sonawane HK, Khandare RS, Parewal K, Shaikh SA, Chaudhari N, et al. Optimizing patient care: An inclusive review of polypharmacy and the vital role of pharmacists in mitigation. Intell Hosp. 2025;100006.
Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J, et al. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis. BMC Geriatr. 2022;22(1):601.
Ngcobo NN. Polypharmacy and deprescribing among geriatric patients. Aging Health Res. 2025;5(3):100256.
Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443-52.
Das S, Gnanavel P, Smanla S, Saikia AM, Mishra S, Khare S, et al. Polypharmacy and self-medication among older adults in Indian urban communities: a cross-sectional study. Sci Rep. 2025;15(1):4062.
Bonanno EG, Figueiredo T, Mimoso IF, Morgado MI, Carrilho J, Midão L, et al. Polypharmacy prevalence among older adults based on the Survey of Health, Ageing and Retirement in Europe: an update. J Clin Med. 2025;14(4):1330.
Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020;11:2042098620933741.
Bhagavathula AS, Vidyasagar K, Chhabra M, Rashid M, Sharma R, Bandari DK, et al. Prevalence of polypharmacy, hyperpolypharmacy and potentially inappropriate medication use in older adults in India: a systematic review and meta-analysis. Front Pharmacol. 2021;12:685518.
Alpert PT, Gatlin T. Polypharmacy in older adults. Home Healthc Now. 2015;33(10):524-9.
Varghese D, Ishida C, Patel P. Polypharmacy. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
Aggarwal P, Woolford SJ, Patel HP. Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice. Geriatrics (Basel). 2020;5(4):85.
Osanlou R, Walker L, Hughes DA, Burnside G, Pirmohamed M. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions. BMJ Open. 2022;12(7).
Maher RL Jr, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
González-Bueno J, Sevilla-Sánchez D, Puigoriol-Juvanteny E, Molist-Brunet N, Codina-Jané C, Espaulella-Panicot J. Factors associated with medication non-adherence among patients with multimorbidity and polypharmacy admitted to an intermediate care center. Int J Environ Res Public Health. 2021;18(18):9606.
Jin R, Liu C, Chen J, Cui M, Xu B, Yuan P, et al. Exploring medication self-management in polypharmacy: a qualitative systematic review of patients' and healthcare providers' perspectives. Front Pharmacol. 2024;15:1426777.
Srivastava SB. Polypharmacy, unintended consequences, and impact of lifestyle medicine. Am J Lifestyle Med. 2024;18(1):54-7.
Ie K, Machino R, Albert SM, Tomita S, Ohashi H, Motohashi I, et al. Proactive deprescribing among older adults with polypharmacy: barriers and enablers. Ann Fam Med. 2025;23(3):207-13.
Famuyiro T, Montas A, Tanoos T, Obinyan TE, Raji M. Deprescribing in real time: hospitalized septuagenarian with polypharmacy. Cureus. 2023;15(6).
Chock YL, Wee YL, Gan SL, Teoh KW, Ng KY, Lee SWH. How willing are patients or their caregivers to deprescribe: a systematic review and meta-analysis. J Gen Intern Med. 2021;36(12):3830-40.
Krustev T, Milushewa P, Tachkov K. Impact of polypharmacy, drug-related problems, and potentially inappropriate medications in geriatric patients and its implications for Bulgaria: narrative review and meta-analysis. Front Public Health. 2022;10:743138.
Eissa A, Lofters A, Nnorom O. Addressing COVID-19 vaccine distrust among Black patients: the LEAPS framework and Afrocentric approaches in medical education. Ann Fam Med. 2023;21(Suppl 1):4439.
Akintayo-Usman NO. Fragmentation of care: a major challenge for older people living with multimorbidity. Geriatr Gerontol Aging. 2021;15.
Hoel RW, Giddings Connolly RM, Takahashi PY. Polypharmacy management in older patients. Mayo Clin Proc. 2021;96(1):242-56.
Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc. 2020;21(2):181-7.
Talukdar IH, Thant PE, Saha S. Consequences of polypharmacy among people living with dementia: a systematic review and meta-analysis. Aging Ment Health. 2025;29(5):767-78.
Maher RL Jr, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
Abu-Naser D. Impact of clinical pharmacist interventions in prescribing errors in hospitalized diabetic patients with major polypharmacy. Hosp Pharm. 2021;56(4):392-9.
Ouraou R, Cossette B, Perron ME, Hudon C. Pharmacists' role in interventions addressing excessive polypharmacy: a scoping review. Int J Clin Pharm. 2026;48(1):17-26.
Horace AE, Ahmed F. Polypharmacy in pediatric patients and opportunities for pharmacists' involvement. Integr Pharm Res Pract. 2015;4:113-26.
Rubio-Valera M, Chen TF, O'Reilly CL. New roles for pharmacists in community mental health care: a narrative review. Int J Environ Res Public Health. 2014;11(10):10967-90.
Hasan Ibrahim AS, Barry HE, Hughes CM. A systematic review of general practice-based pharmacists' services to optimize medicines management in older people with multimorbidity and polypharmacy. Fam Pract. 2021;38(4):509-23.
McAdam C, O'Dwyer E, Dalton K. Pharmacist-led deprescribing interventions for cancer patients in a specialist palliative care setting. Support Care Cancer. 2025;33(4):321.
Shrestha S, Shrestha S, Khanal S. Polypharmacy in elderly cancer patients: challenges and the way clinical pharmacists can contribute in resource-limited settings. Aging Med (Milton). 2019;2(1):42-9.
Greeshma M, Lincy S, Maheswari E, Tharanath S, Viswam S. Identification of drug-related problems by clinical pharmacist in prescriptions with polypharmacy: a prospective interventional study. J Young Pharm. 2018;10(4):460-5.
Hailu BY, Berhe DF, Gudina EK, Gidey K, Getachew M. Drug-related problems in admitted geriatric patients: the impact of clinical pharmacist interventions. BMC Geriatr. 2020;20(1):13.
Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33(13):1453-9.
Li S, Huang L, Chen Z, Zeng L, Li H, Diao S, et al. Tools for identifying potentially inappropriate prescriptions for children and their applicability in clinical practices: a systematic review. Front Pharmacol. 2022;13:787113.
Wallerstedt SM, Svensson SA, Lönnbro J, Hieronymus F, Fastbom J, Hoffmann M, et al. Performance of 3 sets of criteria for potentially inappropriate prescribing in older people to identify inadequate drug treatment. JAMA Netw Open. 2022;5(10).
Keller MS, Qureshi N, Mays AM, Sarkisian CA, Pevnick JM. Cumulative update of a systematic overview evaluating interventions addressing polypharmacy. JAMA Netw Open. 2024;7(1).
Anlay DZ, Paque K, Van Leeuwen E, Cohen J, Dilles T. Tools and guidelines to assess the appropriateness of medication and aid deprescribing: an umbrella review. Br J Clin Pharmacol. 2024;90(1):12-6.
Li KK, Holbrook AM, Thabane L, Teo KK. A survey of physicians showing a one-third reduction in harmful outcomes to be a clinically important difference for statin therapy. J Clin Epidemiol. 2012;65(9):954-61.
Badri B, Stacey S, Konwinski B. Clinical management of polypharmacy in the elderly population. Osteopath Fam Physician. 2023;15(3):18-22.
Gangannagaripalli J, Porter I, Davey A, Ricci-Cabello I, Greenhalgh J, Anderson R, et al. STOPP/START interventions to improve medicines management for people aged 65 years and over: a realist synthesis. Health Serv Deliv Res. 2021;9(23):1-18.
Brooks CF, Argyropoulos A, Matheson-Monnet CB, Kryl D. Evaluating the impact of a polypharmacy action learning sets tool on healthcare practitioners' confidence, perceptions and experiences of stopping inappropriate medicines. BMC Med Educ. 2022;22(1):499.
Ulley J, Harrop D, Ali A, Alton S, Fowler Davis S. Deprescribing interventions and their impact on medication adherence in community-dwelling older adults with polypharmacy: a systematic review. BMC Geriatr. 2019;19(1):15.
Mouazer A, Léguillon R, Boudegzdame N, Levrard T, Le Bars Y, Simon C, et al. ABiMed: an intelligent and visual clinical decision support system for medication reviews and polypharmacy management. arXiv. 2025;25(1):173.
McGrory F, Elnaem MH. Pharmacist-led interventions for polypharmacy management in older adults: a systematic review of strategies and outcomes in the United Kingdom and the Republic of Ireland. Pharmacy (Basel). 2025;13(4):109.
Veronese N, Gallo U, Boccardi V, Demurtas J, Michielon A, Taci X, et al. Efficacy of deprescribing on health outcomes: an umbrella review of systematic reviews with meta-analysis of randomized controlled trials. Ageing Res Rev. 2024;95:102237.
World Health Organization. Medication safety in polypharmacy. 2019. Available at: who.int/publica tions-detail-redirect/medication-safety-in-polypharm acy-technical-report. Accessed on 15 May 2026.
Keller MS, Qureshi N, Mays AM, Sarkisian CA, Pevnick JM. Cumulative update of a systematic overview evaluating interventions addressing polypharmacy. JAMA Netw Open. 2024;7(1).
Kurczewska-Michalak M, Lewek P, Jankowska-Polańska B, Giardini A, Granata N, Maffoni M, et al. Polypharmacy management in older adults: a scoping review of available interventions. Front Pharmacol. 2021;12:734045.
Doherty AJ, Boland P, Reed J, Clegg AJ, Stephani AM, Williams NH, et al. Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 2020;4(3).
Downloads
Published
How to Cite
Issue
Section
